Clay Siegall is a recognized professional in the genetics and biotechnology industry. He has significantly assisted in bettering cancer treatments. Siegall is one of Seattle Genetics’ co-founders and also serves as the CEO of the firm. He has joined efforts with research experts to develop great cures that can be used in cancer treatment since chemotherapies have serious side effects on the human body. Seattle Genetics entered the industry as an average biotechnology company, and it is currently recognized due to the positive impact that it has made in the pharmaceuticals sector. The company has advanced its technology to develop customized cures that can be used in the treatment of a particular individual.
Dr. Siegall was motivated to start creating cancer therapies after discovering the adverse effects of chemotherapies. His goal has been to develop drugs that do not cause harm to the human body. Some products of the biotechnology company are FDA-approved, and they have been commercialized in the United States and other parts of the globe. The firm currently makes profits that enable it to be sustainable. The initial growth of Seattle Genetics depended on money from investors. The IPO of the enterprise was held in 2001, and it made about $675 million from various funding programs.
Seattle Genetics has played a significant role in the success of Clay Siegall’s career. Before establishing the enterprise, he was employed by Bristol-Myers Squibb Pharmaceutical Research Institute and served the firm as from 1991 to 1997. He was a lead researcher at the National Institute of Health where he worked as from 1988 to 1991. Clay Siegall was also hired by the National Cancer Institute.
The growth of the Seattle Genetic in the pharmaceuticals industry was facilitated by the development of the antibody-drug conjugates technology (ADCs). The company has committed itself to developing the technology over the years, and it got an FDA approval in 2011 for a drug that is known as ADCETRIS. To date, Seattle Genetics has developed more than 20 ADCs, and it sells them in the international markets. The company manufactures its products internally and externally by working with companies such as Takeda Pharmaceutical Company, Bayer, and Genentech.